Adverse effect | Grade | Â | |||
---|---|---|---|---|---|
1 | n (%) 2 | 3 | 4 | Total | |
n (%) | n (%) | n (%) | n (%) | n (%) | |
Application site erythema | 2 (6.3) | 1 (3.1) | - | - | 3 (9.4) |
Application site pain | 1 (3.1) | 1 (3.1) | - | - | 2 (6.3) |
Application site pruritus | 1 (3.1) | 1 (3.1) | - | - | 2 (6.3) |
Application site rash | 1 (3.1) | - | - | - | 1 (3.1) |
Application site reaction | 9 (28.1) | 5 (15.6) | - | - | 14 (43.8) |
Application site swelling | 1 (3.1) | Â | Â | Â | 1 (3.1) |
Cerebral ischaemia | - | - | - | 1 (3.1) | 1 (3.1) |
Chills | 1 (3.1) | - | - | - | 1 (3.1) |
Decreased appetite | - | 1 (3.1) | - | - | 1 (3.1) |
Diarrhoea | 1 (3.1) | - | - | - | 1 (3.1) |
Dizziness | 1 (3.1) | - | - | - | 1 (3.1) |
Drug eruption | 1 (3.1) | 1 (3.1) | - | - | 2 (6.3) |
Dry mouth | 1 (3.1) | - | - | - | 1 (3.1) |
Dyspnoea | - | - | - | 1 (3.1) | 1 (3.1) |
Erythema | 1 (3.1) | - | - | - | 1 (3.1) |
Fatigue | 3 (9.4) | - | - | - | 3 (9.4) |
Headache | 1 (3.1) | - | - | - | 1 (3.1) |
Hyperglycaemia | - | - | 1 (3.1) | - | 1 (3.1) |
Leukopenia | - | - | - | 1 (3.1) | 1 (3.1) |
Musculoskeletal discomfort | 1 (3.1) | - | - | - | 1 (3.1) |
Nasopharyngitis | 1 (3.1) | - | - | - | 1 (3.1) |
Nausea | - | 1 (3.1) | - | - | 1 (3.1) |
Neutropenia | - | - | - | 1 (3.1) | 1 (3.1) |
Night sweats | 1 (3.1) | - | - | - | 1 (3.1) |
Oedema peripheral | - | 1 (3.1) | - | - | 1 (3.1) |
Pruritus | 4 (12.5) | - | 1 (3.1) | - | 5 (15.6) |
Pyrexia | 2 (6.3) | - | - | - | 2 (6.3) |
Thrombocytopenia | - | - | - | 1 (3.1) | 1 (3.1) |
Venous thrombosis | - | - | 1 (3.1) | - | 1 (3.1) |
Vision blurred | 1 (3.1) | - | - | - | 1 (3.1) |
Vulvovaginal mycotic infection | 1 (3.1) | - | - | - | 1 (3.1) |
Weight decreased | - | 1 (3.1) | - | - | 1 (3.1) |
Weight increased | 1 (3.1) | - | - | - | 1 (3.1) |